Multimodal Computed Tomography in Patients With Acute Hemorrhagic Stroke
ConditionAcute Hemorrhagic Stroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorXiaolin Chen, MD
About this trial
Acute hemorrhagic stroke is a series of neurosurgical diseases characterized by bleeding with high morbidity and mortality. It accounts for about 20% of all strokes worldwide and mainly includes subtypes such as intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). Multimodal computed tomography including non-contrast computed tomography, computed tomography angiography and computed tomography perfusion, is of great important in understanding pathophysiological changes, evaluating prognosis and guiding interventions in these diseases.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age ≥ 18, ≤ 85 years;
presence with hemorrhagic stroke
Disqualifiers
with a history of previous history of ischemic/hemorrhagic stroke;
admission to the emergency department more than a week after symptom onset;
serious medical history or existing comorbidities;
physical disability due to previous diseases;
Trial population
Patients presented to the emergency department with hemorrhagic stroke.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Multimodal CT
DeviceNon-contrast computed tomography, computed tomography angiography and computed tomography perfusion
Treatment groups
10,000 Participants
are divided into 1 treatment groupGroup A: Testing populations1 intervention
Trial outcomes
Primary outcomes
1
modified Rankin Scale (mRS)
The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. No significant disability. Able to carry out all usual activities, despite some symptoms. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. Moderate disability. Requires some help, but able to walk unassisted. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. Dead
Time frame
At 3/6/12 months after onsetSecondary outcomes
1
Mortality rate
Mortality rate as measured by death of a participant (binary outcome (yes/no)
Time frame
At 12 months after onset2
Total time spent on the intensive care unit (ICU)/stroke unit
The total time spent on the intensive care unit (ICU)/stroke unit as a continuous variable from the first admission to the ICU/stroke unit to discharge from ICU/stroke unit
Time frame
After treatment (max 60 days)3
Non-neurological systemic complications
This category of diseases mainly refers to a series of non-neurological systemic complication such as electrolyte alterations, cardiovascular complications, pneumonia, gastrointestinal alterations, coagulation disorders and so on
Time frame
After onset (max 60 days)4
Delayed infarction
Delayed onset of any type of infarction detected by NCCT/MRI/CTP after surgical treatment or during conservative treatment
Time frame
After onset (max 30 days)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Xiaolin Chen, MD
Lead sponsor
Beijing Tiantan Hospital
Sponsor institution
Peking University International Hospital
Collaborator
Zhangzhou Municipal Hospital of Fujian Province
Collaborator
The First Affiliated Hospital of Shanxi Medical University
Collaborator
Santai County People's Hospital
Collaborator
Jiujiang No.1 People's Hospital
Collaborator
Qin Zhou NO.1 People's Hospital
Collaborator
Sichuan Academy of Medical Sciences
Collaborator
Linyi People's Hospital
Collaborator
Source ClinicalTrials.gov